Quantitative immunofluorescence reveals the signature of active B-cell receptor signaling in diffuse large B-cell lymphoma

Clinical Cancer Research

Volumn 18, Issue 22, 2012, Pages 6122-6135

  Bogusz, Agata M ^a,d   Baxter, Richard H G ^c   Currie, Treeve ^a   Sinha, Papiya ^a   Sohani, Aliyah R ^b   Kutok, Jeffery L ^a,e   Rodig, Scott J ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c YALE UNIVERSITY   (United States)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e Infinity Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B LYMPHOCYTE RECEPTOR; BRUTON TYROSINE KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN KINASE LYN; PROTEIN KINASE SYK; TRANSCRIPTION FACTOR FKHR;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOPLASM; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE; INTRACELLULAR SIGNALING; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN CROSS LINKING; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; QUANTITATIVE IMMUNOFLUORESCENCE;

ADULT; AGED; AGED, 80 AND OVER; CELL LINE, TUMOR; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MICROSCOPY, FLUORESCENCE; MIDDLE AGED; PHOSPHOPROTEINS; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN TRANSPORT; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, ANTIGEN, B-CELL; SIGNAL TRANSDUCTION; SRC-FAMILY KINASES; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84869213410     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-0397     Document Type: Article

References (55)

1. Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol 1998;16:2780-95. (Pubitemid 28363044)
2. Hunt KE, Reichard KK. Diffuse large B-cell lymphoma. Arch Pathol Lab Med 2008;132:118-24.
3. Abramson JS, Shipp MA. Advances in the biology and therapy of diffuse large B-cell lymphoma: moving toward a molecularly targeted approach. Blood 2005;106:1164-74. (Pubitemid 41129574)
4. Coiffier B. Rituximab therapy in malignant lymphoma. Oncogene 2007;26:3603-13. (Pubitemid 46844778)
5. Lam K-P, Kühn R, Rajewsky K. In vivo ablation of surface immunoglobulin on mature B cells by inducible gene targeting results in rapid cell death. Cell 1997;90:1073-83. (Pubitemid 27408521)
6. Chan WC. Pathogenesis of diffuse large B cell lymphoma. Int J Hematol 2010;92:219-30.
7. Witzig TE, Gupta M. Signal transduction inhibitor therapy for lymphoma. Hematology Am Soc Hematol Educ Program 2010;2010:265-70.
8. Rajewsky K, Kanzler H, Hansmann M-L, Küppers R. Normal and malignant B-cell development with special reference to Hodgkin's disease. Ann Oncol 1997;8 Suppl 2:79-81.
9. Kraus M, Alimzhanov MB, Rajewsky N, Rajewsky K. Survival of resting mature B lymphocytes depends on BCR signaling via the Igalpha/beta heterodimer. Cell 2004;117:787-800. (Pubitemid 38748894)
10. Dal Porto JM, Gauld SB, Merrell KT, Mills D, Pugh-Bernard AE, Cambier J. B cell antigen receptor signaling 101. Mol Immunol 2004;41:599-613. (Pubitemid 38824617)
11. Saouaf SJ, Mahajan S, Rowley RB, Kut SA, Fargnoli J, Burkhardt AL, et al. Temporal differences in the activation of three classes of non-transmembrane protein tyrosine kinases following B-cell antigen receptor surface engagement. Proc Natl Acad Sci U S A 1994;91:9524-8.
12. Cheng AM, Rowley B, Pao W, Hayday A, Bolen JB, Pawson T. Syk tyrosine kinase required for mouse viability and B-cell development. Nature 1995;378:303-6.
13. Cornall RJ, Cheng AM, Pawson T, Goodnow CC. Role of Syk in B-cell development and antigen-receptor signaling. Proc Natl Acad Sci US A 2000;97:1713-8. (Pubitemid 30118508)
14. Turner M, Mee PJ, Costello PS, Williams O, Price AA, Duddy LP, et al. Perinatal lethality and blocked B-cell development in mice lacking the tyrosine kinase Syk. Nature 1995;378:298-302.
15. Gold MR, Scheid MP, Santos L, Dang-Lawson M, Roth RA, Matsuuchi L, et al. The B cell antigen receptor activates the Akt (protein kinase B)/glycogen synthase kinase-3 signaling pathway via phosphatidylinositol 3-kinase. J Immunol 1999;163:1894-905. (Pubitemid 29382190)
16. Aagaard-Tillery KM, Jelinek DF. Phosphatidylinositol 3-kinase activation in normal human B lymphocytes. J Immunol 1996;156:4543-54.
17. Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS, et al. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 1999;96:857-68. (Pubitemid 29165088)
18. Maiese K, Chong ZZ, Shang YC, Hou J. A "FOXO" in sight: targeting Foxo proteins from conception to cancer. Med Res Rev 2009;29:395-418.
19. Fillmore GC, Wang Q, Carey MJ, Kim C-H, Elenitoba-Johnson KSJ, Lim MS. Expression of Akt (protein kinase B) and its isoforms in malignant lymphomas. Leuk Lymphoma 2005;46:1765-73. (Pubitemid 43203112)
20. Lenz G, Staudt LM. Aggressive lymphomas. N Engl J Med 2010;362:1417-29.
21. Davis RE, Ngo VN, Lenz G, Tolar P, Young RM, Romesser PB, et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 2010;463:88-92.
22. Chen L, Monti S, Juszczynski P, Daley J, Chen W, Witzig TE, et al. SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma. Blood 2008;111:2230-7. (Pubitemid 351451430)
23. Monti S, Savage KJ, Kutok JL, Feuerhake F, Kurtin P, Mihm M, et al. Molecular profiling of diffuse large B-cell lymphoma identi fies robust subtypes including one characterized by host inflammatory response. Blood 2005;105:1851-61. (Pubitemid 40731764)
24. Cheng S, Coffey G, Zhang XH, Shaknovich R, Song Z, Lu P, et al. SYK inhibition and response prediction in diffuse large B-cell lymphoma. Blood 2011;118:6342-52.
25. Friedberg JW, Sharman J, Sweetenham J, Johnston PB, Vose JM, Lacasce A, et al. Inhibition of Syk with fostamatinib disodium has signi ficant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 2010;115:2578-85.
26. de Rooij MF, Kuil A, Geest CR, Eldering E, Chang BY, Buggy JJ, et al. The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. Blood 2012;119:2590-4.
27. Hoellenriegel J, Meadows SA, Sivina M, Wierda WG, Kantarjian H, Keating MJ, et al. The phosphoinositide 30 -kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood 2011;118:3603-12.
28. Juszczynski P, Chen L, O'Donnell E, Polo JM, Ranuncolo SM, Dalla-Favera R, et al. BCL6 modulates tonic BCR signaling in diffuse large Bcell lymphomas by repressing the SYK phosphatase, PTPROt. Blood 2009;114:5315-21.
29. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998;4:844-7. (Pubitemid 28331029)
30. Ripley BD, Thompson M. Regression techniques for the detection of analytical bias. Analyst 1987;112:377-83.
31. Yamanashi Y, Kakiuchi T, Mizuguchi J, Yamamoto T, Toyoshima K. Association of B cell antigen receptor with protein tyrosine kinase Lyn. Science 1991;251:192-4. (Pubitemid 21916867)
32. Burkhardt AL, Brunswick M, Bolen JB, Mond JJ. Anti-immunoglobulin stimulation of B lymphocytes activates src-related protein-tyrosine kinases. Proc Natl Acad Sci U S A 1991;88:7410-4. (Pubitemid 21915161)
33. Geahlen RL. Syk and pTyr'd: signaling through the B cell antigen receptor. Biochim Biophys Acta 2009;1793:1115-27.
34. Keshvara LM, Isaacson CC, Yankee TM, Sarac R, Harrison ML, Geahlen RL. Syk- and Lyn-dependent phosphorylation of Syk on multiple tyrosines following B cell activation includes a site that negatively regulates signaling. J Immunol 1998;161:5276-83. (Pubitemid 28519087)
35. Rawlings DJ, Scharenberg AM, Park H, Wahl MI, Lin S, Kato RM, et al. Activation of BTK by a phosphorylation mechanism initiated by SRC family kinases. Science 1996;271:822-5. (Pubitemid 26058937)
36. Nisitani S, Kato RM, Rawlings DJ, Witte ON, Wahl MI. In situ detection of activated Bruton's tyrosine kinase in the Ig signaling complex by phosphopeptide-specific monoclonal antibodies. Proc Natl Acad Sci U S A 1999;96:2221-6. (Pubitemid 29117895)
37. Zhou F, Hu J, Ma H, Harrison ML, Geahlen RL. Nucleocytoplasmic trafficking of the Syk protein tyrosine kinase. Mol Cell Biol 2006;26:3478-91.
38. Luangdilok S, Box C, Patterson L, Court W, Harrington K, Pitkin L, et al. Syk tyrosine kinase is linked to cell motility and progression in squamous cell carcinomas of the head and neck. Cancer Res 2007;67:7907-16. (Pubitemid 47281387)
39. Wang L, Duke L, Zhang PS, Arlinghaus RB, Symmans WF, Sahin A, et al. Alternative splicing disrupts a nuclear localization signal in spleen tyrosine kinase that is required for invasion suppression in breast cancer. Cancer Res 2003;63:4724-30. (Pubitemid 36951053)
40. Pighi C, Gu T-L, Dalai I, Barbi S, Parolini C, Bertolaso A, et al. Phosphoproteomic analysis of mantle cell lymphoma cells suggests a prosurvival role of B-cell receptor signaling. Cell Oncol (Dordr) 2011;34:141-53.
41. Baker AF, Dragovich T, Ihle NT, Williams R, Fenoglio-Preiser C, Powis G. Stability of phosphoprotein as a biological marker of tumor signaling. Clin Cancer Res 2005;11:4338-40. (Pubitemid 40825621)
42. Srinivasan L, Sasaki Y, Calado DP, Zhang B, Paik JH, DePinho RA, et al. PI3 kinase signals BCR-dependent mature B cell survival. Cell 2009;139:573-86.
43. Bai Y, Tolles J, Cheng H, Siddiqui S, Gopinath A, Pectasides E, et al. Quantitative assessment shows loss of antigenic epitopes as a function of pre-analytic variables. Lab Invest 2011;91:1253-61.
44. Pinhel IF, Macneill FA, Hills MJ, Salter J, Detre S, A'Hern R, et al. Extreme loss of immunoreactive p-Akt and p-Erk1/2 during routine fixation of primary breast cancer. Breast Cancer Res 2010;12:R76.
45. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression pro filing. Nature 2000;403:503-11. (Pubitemid 30082188)
46. Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004;103:275-82. (Pubitemid 38029949)
47. Aoki M, Jiang H, Vogt PK. Proteasomal degradation of the FoxO1 transcriptional regulator in cells transformed by the P3k and Akt oncoproteins. Proc Natl Acad Sci U S A 2004;101:13613-7. (Pubitemid 39238451)
48. Perrot V, Rechler MM. The coactivator p300 directly acetylates the forkhead transcription factor Foxo1 and stimulates Foxo1-induced transcription. Mol Endocrinol 2005;19:2283-98. (Pubitemid 41258099)
49. Dahia PL, Aguiar RC, Alberta J, Kum JB, Caron S, Sill H, et al. PTEN is inversely correlated with the cell survival factor Akt/PKB and is inactivated via multiple mechanismsin haematological malignancies. Hum Mol Genet 1999;8:185-93. (Pubitemid 29054260)
50. Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2002;2:489-501. (Pubitemid 37328931)
51. Ravetch JV, Lanier LL. Immune inhibitory receptors. Science 2000;290:84-9.
52. Scapini P, Pereira S, Zhang H, Lowell CA. Multiple roles of Lyn kinase in myeloid cell signaling and function. Immunol Rev 2009;228:23-40.
53. Pham LV, Fu L, Tamayo AT, Bueso-Ramos C, Drakos E, Vega F, et al. Constitutive BR3 receptor signaling in diffuse, large B-cell lymphomas stabilizes nuclear factor-kappaB-inducing kinase while activating both canonical and alternative nuclear factor-kappaB pathways. Blood 2011;117:200-10.
54. Ding H, Gabali AM, Jenson SD, Lim MS, Elenitoba-Johnson KSJ. P38 mitogen activated protein kinase expression and regulation by interleukin-4 in human B cell non-Hodgkin lymphomas. J Hematop 2009;2:195-204.
55. Singh RR, Kim JE, Davuluri Y, Drakos E, Cho-Vega JH, Amin HM, et al. Hedgehog signaling pathway is activated in diffuse large B-cell lymphoma and contributes to tumor cell survival and proliferation. Leukemia 2010;24:1025-36.